Napo Pharmaceuticals announced the activation by the U.S. Food and Drug Administration of the Investigational New Drug application for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease, an ultra-rare congenital diarrheal disorder.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on JAGX:
- Jaguar Health announces results of independent study on crofelemer
- Jaguar Health announces FDA activation of third-party IND for crofelemer
- Biotech Alert: Searches spiking for these stocks today
- Jaguar Health names Principal Investigators for Canalevia-CA1 trial
- Jaguar Health’s Napo submits IND application for crofelemer powder formulation